> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Updates Actos Bladder Cancer Risk
- URL: https://www.fdaweb.com/fda-updates-actos-bladder-cancer-risk/
- Published: 2016-12-12T12:00:00.000Z
- Updated: 2026-09-14T21:53:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137547

FDA says that as a result of an updated review, it has determined that using the Type 2 diabetes medicine pioglitazone (Takeda’s Actos, Actoplus Met, Actoplus Met XR, and generic combination drugs Duetact and Oseni) may be linked to an increased risk of bladder cancer. An agency drug safety [communication](http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) says that the labels of drugs containing pioglitazone already contain Warnings about the risk, and FDA has now approved labeling updates to describe the additional studies it reviewed.

The communication says that healthcare professionals should not use pioglitazone in patients with active bladder cancer, and should carefully consider the benefits and risks before using it in patients with a history of bladder cancer.